{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T21:02:54Z","timestamp":1762376574592,"version":"build-2065373602"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,6,13]],"date-time":"2019-06-13T00:00:00Z","timestamp":1560384000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA008748","U10CA180821","U10CA180838","U10CA180867","U10CA180882"],"award-info":[{"award-number":["P30 CA008748","U10CA180821","U10CA180838","U10CA180867","U10CA180882"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.ejca.2019.06.002","type":"journal-article","created":{"date-parts":[[2019,7,2]],"date-time":"2019-07-02T06:22:06Z","timestamp":1562048526000},"page":"91-98","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor\u2013positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM\/2006-11_GBG51) and CALGB 40503 (Alliance) trials"],"prefix":"10.1016","volume":"117","author":[{"given":"M.","family":"Mart\u00edn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Loibl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Hyslop","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"De la Haba-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Aktas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.T.","family":"Cirrincione","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.T.","family":"Barry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Morales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.A.","family":"Carey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.A.","family":"Garcia-Saenz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Partridge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Martinez-Ja\u00f1ez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Winer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Guerrero-Zotano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Hudis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Casas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Rodriguez-Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Furlanetto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Carrasco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.N.","family":"Dickler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2019.06.002_bib1","doi-asserted-by":"crossref","first-page":"6232","DOI":"10.1158\/0008-5472.CAN-07-5654","article-title":"Vascular endothelial growth factor reduces tamoxifen efficacy and promotes metastatic colonization and desmoplasia in breast tumors","volume":"68","author":"Qu","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2019.06.002_bib2","first-page":"5407","article-title":"High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer","volume":"61","author":"Foekens","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2019.06.002_bib3","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1200\/JCO.2014.57.2388","article-title":"Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer: the letrozole\/fulvestrant and avastin (LEA) study","volume":"33","author":"Martin","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2019.06.002_bib4","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.1200\/JCO.2015.66.1595","article-title":"Phase III trial evaluating letrozole as first-line endocrine therapy with or without bevacizumab for the treatment of postmenopausal women with hormone receptor-positive advanced-stage breast cancer: CALGB 40503 (alliance)","volume":"34","author":"Dickler","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2019.06.002_bib5","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1080\/01621459.1989.10478874","article-title":"The robust inference for the proportional hazards model","volume":"84","author":"Lin DYW","year":"1989","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.ejca.2019.06.002_bib6","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1093\/annonc\/mdt276","article-title":"First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients","volume":"24","author":"Miles","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2019.06.002_bib7","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1056\/NEJMoa072113","article-title":"Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer","volume":"357","author":"Miller","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2019.06.002_bib8","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1200\/JCO.2008.21.6457","article-title":"Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer","volume":"28","author":"Miles","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2019.06.002_bib9","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1200\/JCO.2010.28.0982","article-title":"RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer","volume":"29","author":"Robert","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2019.06.002_bib10","doi-asserted-by":"crossref","first-page":"4286","DOI":"10.1200\/JCO.2010.34.1255","volume":"29","author":"Brufsky","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2019.06.002_bib11","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1200\/JCO.2011.35.7376","article-title":"First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study","volume":"30","author":"Bergh","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2019.06.002_bib12","first-page":"585","article-title":"RESILIENCE: phase III randomized, double-blind trial comparing sorafenib with capecitabine versus placebo with capecitabine in locally advanced or metastatic HER2-negative breast cancer","volume":"17","author":"Baselga","year":"2017","journal-title":"Clin Breast Canc"},{"key":"10.1016\/j.ejca.2019.06.002_bib13","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1200\/JCO.2010.31.2975","article-title":"Randomized, placebo-controlled, double-blind, phase II study of axitinib plus docetaxel versus docetaxel plus placebo in patients with metastatic breast cancer","volume":"29","author":"Rugo","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2019.06.002_bib14","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S1470-2045(11)70037-7","article-title":"Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study","volume":"12","author":"Martin","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2019.06.002_bib15","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1111\/j.1349-7006.1994.tb02904.x","article-title":"Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary breast cancer","volume":"85","author":"Toi","year":"1994","journal-title":"Jpn J Cancer Res"},{"key":"10.1016\/j.ejca.2019.06.002_bib16","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.ctrv.2011.12.002","article-title":"Controlling angiogenesis in breast cancer: a systematic review of anti-angiogenic trials","volume":"38","author":"Mackey","year":"2012","journal-title":"Cancer Treat Rev"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804919303600?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804919303600?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:24:18Z","timestamp":1760732658000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804919303600"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":16,"alternative-id":["S0959804919303600"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2019.06.002","relation":{},"ISSN":["0959-8049"],"issn-type":[{"type":"print","value":"0959-8049"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor\u2013positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM\/2006-11_GBG51) and CALGB 40503 (Alliance) trials","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2019.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}